中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
Chinese Journal of Biochemical Pharmaceutics
2015年
10期
102-104
,共3页
急性脑梗死%神经功能缺陷程度%重组组织型纤溶酶原激活剂
急性腦梗死%神經功能缺陷程度%重組組織型纖溶酶原激活劑
급성뇌경사%신경공능결함정도%중조조직형섬용매원격활제
acute cerebral infarction%neurological defects%recombinant tissue plasminogen activator
目的 探究与分析不同剂量的重组组织型纤溶酶原激活剂(recombinant tissue-type plasminogen activator,rt-PA)静脉溶栓治疗急性脑梗死的疗效.方法 选取2014年5月~2015年5月进行rt-PA静脉溶栓治疗的80例急性脑梗死患者作为研究对象,根据rt-PA静脉溶栓剂使用剂量的不同分成2组,每组40例.以溶栓治疗后24 h内脑出血(intracerebral hemorrhage,ICH)、症状性脑出血(symptomatic intracerebral hemorrhage,SICH)、其他出血症状及治疗后3个月预后良好率、总死亡率评价治疗的临床疗效.通过NIHSS评分对治疗前、后2组患者的神经功能缺陷程度进行评分,分析2组治疗临床疗效与治疗前神经功能缺陷程度之间的相关性.结果 标准剂量组溶栓治疗后3个月总死亡率明显高于低剂量组(P<0.05).治疗后低剂量组NIHSS评分4~8分的比例明显多于标准剂量组(P<0.05);低剂量组NIHSS评分9~16分、17~24分的比例均明显少于标准剂量组(P<0.05).标准剂量组NIHSS 9~16分的患者治疗后3个月的总死亡率明显高于低剂量组(P<0.05).结论 不同剂量的rt-PA静脉溶栓治疗急性脑梗死的疗效基本一致,且疗效不受神经功能缺陷程度的影响,但低剂量rt-PA治疗时更能减少患者3个月后的死亡率.
目的 探究與分析不同劑量的重組組織型纖溶酶原激活劑(recombinant tissue-type plasminogen activator,rt-PA)靜脈溶栓治療急性腦梗死的療效.方法 選取2014年5月~2015年5月進行rt-PA靜脈溶栓治療的80例急性腦梗死患者作為研究對象,根據rt-PA靜脈溶栓劑使用劑量的不同分成2組,每組40例.以溶栓治療後24 h內腦齣血(intracerebral hemorrhage,ICH)、癥狀性腦齣血(symptomatic intracerebral hemorrhage,SICH)、其他齣血癥狀及治療後3箇月預後良好率、總死亡率評價治療的臨床療效.通過NIHSS評分對治療前、後2組患者的神經功能缺陷程度進行評分,分析2組治療臨床療效與治療前神經功能缺陷程度之間的相關性.結果 標準劑量組溶栓治療後3箇月總死亡率明顯高于低劑量組(P<0.05).治療後低劑量組NIHSS評分4~8分的比例明顯多于標準劑量組(P<0.05);低劑量組NIHSS評分9~16分、17~24分的比例均明顯少于標準劑量組(P<0.05).標準劑量組NIHSS 9~16分的患者治療後3箇月的總死亡率明顯高于低劑量組(P<0.05).結論 不同劑量的rt-PA靜脈溶栓治療急性腦梗死的療效基本一緻,且療效不受神經功能缺陷程度的影響,但低劑量rt-PA治療時更能減少患者3箇月後的死亡率.
목적 탐구여분석불동제량적중조조직형섬용매원격활제(recombinant tissue-type plasminogen activator,rt-PA)정맥용전치료급성뇌경사적료효.방법 선취2014년5월~2015년5월진행rt-PA정맥용전치료적80례급성뇌경사환자작위연구대상,근거rt-PA정맥용전제사용제량적불동분성2조,매조40례.이용전치료후24 h내뇌출혈(intracerebral hemorrhage,ICH)、증상성뇌출혈(symptomatic intracerebral hemorrhage,SICH)、기타출혈증상급치료후3개월예후량호솔、총사망솔평개치료적림상료효.통과NIHSS평분대치료전、후2조환자적신경공능결함정도진행평분,분석2조치료림상료효여치료전신경공능결함정도지간적상관성.결과 표준제량조용전치료후3개월총사망솔명현고우저제량조(P<0.05).치료후저제량조NIHSS평분4~8분적비례명현다우표준제량조(P<0.05);저제량조NIHSS평분9~16분、17~24분적비례균명현소우표준제량조(P<0.05).표준제량조NIHSS 9~16분적환자치료후3개월적총사망솔명현고우저제량조(P<0.05).결론 불동제량적rt-PA정맥용전치료급성뇌경사적료효기본일치,차료효불수신경공능결함정도적영향,단저제량rt-PA치료시경능감소환자3개월후적사망솔.
Objective To explore different doses of recombinant tissue-type plasminogen activator (rt-PA) intravenous thrombolytic therapy for acute cerebral infarction.Methods 130 patients with acute cerebral infarction were as the research subjects selected from May 2014 to May 2015 for rt-PA thrombolytic therapy, who were divided into two groups according to rt-PA thrombolytic agent dose, 65 cases in each group.Evaluated the clinical efficacy of thrombolytic therapy after treatment in accordance within 24 h intracerebral hemorrhage (ICH) , symptomatic intracerebral hemorrhage (SICH) , other bleeding symptoms and for 3 months after treatment the prognosis was good rate, total mortality.For pre-treatment, the degree of defect nerve function after two groups of patients were scored by NIHSS score, correlation analysis between the two groups of clinical efficacy and function of the degree of nerve defect before treatment.Results 3 months after thrombolysis total mortality in the standard dose group was significantly higher than that in the low-dose group (P<0.05) .After treatment, both groups NIHSS scores were significantly lower than before treatment (P<0.05); After treatment, NIHSS score 4-8 points in the proportion of low-dose group was significantly more than that in the standard dose group (P<0.05); NIHSS score 9-16 points, 17-24 points in the proportion of low-dose group were significantly less than that in the standard dose group (P<0.05).NIHSS9-16 points of patients after total mortality three months in the standard-dose group was significantly higher than that in the low-dose group (P<0.05) . Conclusion Different doses of rt-PA thrombolytic therapy in acute cerebral infarction are basically the same, and the degree of neurological deficit does not affect the efficacy, but reduce mortality in patients 3 months after low-dose rt-PA treatment, it is worth widely used in clinical practice.
